RxDoctor Payments Data

Gerald Koenig, MD

Cardiovascular Disease · Detroit, MINPI 1912025180

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $69,650 of the $95,696 with a category attached, or 72.8%. Bard Peripheral Vascular, Inc. accounts for 83.8% of it on its own, with 17 other manufacturers making up the rest. 2025 is the largest year on record at $77,238, 7.1 times the $10,937 reported in 2019. Among cardiovascular disease clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$95,696in general payments, 2019–2025

Across 114 payments — averaging $839.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bard Peripheral Vascular, Inc.$80K
  • Siemens Medical Solutions USA, Inc.$10K
  • Abbott$2K
  • Abiomed$2K
  • Biocardia, Inc.$224
  • Shockwave Medical, Inc$159
  • plus $564 from 12 others
$578,807in research payments, 2019–2025

Across 64 payments — averaging $9043.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Bard Peripheral Vascular, Inc.$420K
  • ZOLL Circulation Inc$63K
  • Shockwave Medical, Inc$39K
  • Boston Scientific$37K
  • Inari Medical, Inc.$14K
  • Neovasc Medical Inc$6K
  • plus $950 from 1 others

What the payments were for

  • Consulting fees$69,65073%
  • Speaking & faculty fees$1,5002%
  • Travel & lodging$21,97423%
  • Food & beverage$2,5723%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$95,696 in reported general payments places this provider in the 95th percentile of 760 cardiovascular disease providers in Michigan.

See all cardiovascular disease providers in Michigan

Medicare billing

Part B allowed, 2024
$98,034
Medicare patients
226
Services billed
714

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban101$114,147
XareltoRivaroxaban33$42,175
EntrestoSacubitril/Valsartan13$23,341
JardianceEmpagliflozin14$19,093
Praluent PenAlirocumab13$14,194
FarxigaDapagliflozin Propanediol11$8,257
Atorvastatin Calcium182$3,149
Rosuvastatin Calcium102$2,092
Ezetimibe75$2,016
Metoprolol Succinate130$1,876
Losartan Potassium117$1,370
ClopidogrelClopidogrel Bisulfate73$1,359
Isosorbide Mononitrate ErIsosorbide Mononitrate34$816
Flecainide Acetate13$782
Pravastatin Sodium37$690

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Detroit

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →